Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip E Castle

Showing results (41-50 of 490) with videos related to

Pageof 49
Sort By:
Journal of Lower Genital Tract Disease|March 27, 2015
Letter to the editor regarding "Evaluation of a cervicography-based program to ensure quality of visual inspection of the cervix in HIV-infected women in Johannesburg, South Africa" by Firnhaber et alJane J Kim, Philip E Castle
The Lancet. Infectious Diseases|July 5, 2016
Age of human papillomavirus vaccination?Philip E Castle, Emily A Burger
Nature Reviews. Clinical Oncology|June 22, 2016
Screening: A risk-based framework to decide who benefits from screeningPhilip E Castle, Hormuzd A Katki
Lancet (London, England)|September 6, 2014
HPV vaccination: for women of all ages?Philip E Castle, Kathleen M Schmeler
American Family Physician|March 15, 2023
Multicancer Early Detection: A Promise Yet to Be ProvenChyke A Doubeni, Philip E Castle
Epidemiology (Cambridge, Mass.)|September 2, 2005
With or without a gold standardRuth M Pfeiffer, Philip E Castle
Journal of the National Cancer Institute. Monographs|June 17, 2003
Chapter 4: Genital tract infections, cervical inflammation, and antioxidant nutrients--assessing their roles as human papillomavirus cofactorsPhilip E Castle, Anna R Giuliano
The Lancet. Oncology|January 22, 2010
Benefits and risks of HPV testing in cervical cancer screeningPhilip E Castle, Hormuzd A Katki
The Journal of Infectious Diseases|July 12, 2011
Population effectiveness, not efficacy, should decide who gets vaccinated against human papillomavirus via publicly funded programsPhilip E Castle, Fang-Hui Zhao
Gynecologic Oncology|November 13, 2012
Optimizing cervical cancer prevention strategies in the United StatesPhilip E Castle, Kathleen M Schmeler
Pageof 49

Showing results (41-50 of 490) with videos related to

Sort By:
Pageof 49
Journal of Lower Genital Tract Disease|March 27, 2015
Letter to the editor regarding "Evaluation of a cervicography-based program to ensure quality of visual inspection of the cervix in HIV-infected women in Johannesburg, South Africa" by Firnhaber et alJane J Kim, Philip E Castle
The Lancet. Infectious Diseases|July 5, 2016
Age of human papillomavirus vaccination?Philip E Castle, Emily A Burger
Nature Reviews. Clinical Oncology|June 22, 2016
Screening: A risk-based framework to decide who benefits from screeningPhilip E Castle, Hormuzd A Katki
Lancet (London, England)|September 6, 2014
HPV vaccination: for women of all ages?Philip E Castle, Kathleen M Schmeler
American Family Physician|March 15, 2023
Multicancer Early Detection: A Promise Yet to Be ProvenChyke A Doubeni, Philip E Castle
Epidemiology (Cambridge, Mass.)|September 2, 2005
With or without a gold standardRuth M Pfeiffer, Philip E Castle
Journal of the National Cancer Institute. Monographs|June 17, 2003
Chapter 4: Genital tract infections, cervical inflammation, and antioxidant nutrients--assessing their roles as human papillomavirus cofactorsPhilip E Castle, Anna R Giuliano
The Lancet. Oncology|January 22, 2010
Benefits and risks of HPV testing in cervical cancer screeningPhilip E Castle, Hormuzd A Katki
The Journal of Infectious Diseases|July 12, 2011
Population effectiveness, not efficacy, should decide who gets vaccinated against human papillomavirus via publicly funded programsPhilip E Castle, Fang-Hui Zhao
Gynecologic Oncology|November 13, 2012
Optimizing cervical cancer prevention strategies in the United StatesPhilip E Castle, Kathleen M Schmeler
Pageof 49